Clincosm LogoSign in Get a demo

nsclc, stage iii

Showing 1 - 20 of 20
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, Stage III Trial in Indianapolis (Signatera ctDNA test)

Not yet recruiting
  • NSCLC, Stage III
  • Signatera ctDNA test
  • Indianapolis, Indiana
    Indiana University Melvin and Bren Simon Comprehensive Cancer Ce
Mar 13, 2023

NSCLC, Stage III, ALK-rearrangement Trial in Worldwide (Brigatinib, Durvalumab)

Not yet recruiting
  • NSCLC, Stage III
  • ALK-rearrangement
  • Angers, France
  • +19 more
Feb 8, 2023

NSCLC, Stage III Trial in Germany (Durvalumab Injection [Imfinzi], Thoracic Radiotherapy (TRT) conventionally, Thoracic

Recruiting
  • NSCLC, Stage III
  • Durvalumab Injection [Imfinzi]
  • +2 more
  • Aachen, Germany
  • +13 more
Nov 29, 2022

NSCLC, Stage III Trial in Beijing (Tislelizumab, Pemetrexed (Nonsquamous NSCLC) or Paclitaxel/Nab-paclitaxel(Squamous NSCLC),

Recruiting
  • NSCLC, Stage III
  • Beijing, Beijing, China
    Beijing Tsinghua Chang Gung Hospital
Nov 4, 2022

Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc Trial in Stanford (Durvalumab, Carboplatin, Pemetrexed)

Recruiting
  • Non Small Cell Lung Cancer
  • +2 more
  • Stanford, California
    Stanford University
Oct 27, 2022

Oncology, NSCLC Stage IV, NSCLC, Stage III Trial in Drammen (UV1, Sagramostim, Anti-PD-1/PD-L1 treatment)

Recruiting
  • Oncology
  • +2 more
  • UV1
  • +2 more
  • Drammen, Viken, Norway
    Vestre Viken Health Trust
Aug 15, 2022

Lung Cancer, NSCLC, Stage III, NSCLC Stage IV Trial in Drammen (sotorasib)

Recruiting
  • Lung Cancer
  • +6 more
  • Drammen, Viken, Norway
    Vestre Viken Health Trust
May 30, 2022

NSCLC, Stage III Trial in Chengdu (GFH018, Toripalimab, Paclitaxel)

Not yet recruiting
  • NSCLC, Stage III
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
May 23, 2022

Using Microbiome to Predict Durvalumab Toxicity in Post-

Recruiting
  • NSCLC, Stage III
  • Locally Advanced Lung Carcinoma
    • Kansas City, Kansas
    • +1 more
    May 17, 2022

    Non Small Cell Lung Cancer, Lung Cancer, Nsclc Trial in United States (Radiation Therapy, Durvalumab)

    Recruiting
    • Non Small Cell Lung Cancer
    • +4 more
    • Miami, Florida
    • +8 more
    Mar 30, 2022

    NSCLC, Stage III Trial (SHR-1701)

    Not yet recruiting
    • NSCLC, Stage III
    • (no location specified)
    Dec 14, 2021

    Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage III Trial in Worldwide (Durvalumab Injection)

    Recruiting
    • Cancer
    • +4 more
    • Durvalumab Injection
    • Tallinn, Estonia
    • +9 more
    Dec 1, 2021

    NSCLC, Stage III Trial in Pavia (Durvalumab)

    Recruiting
    • NSCLC, Stage III
    • Pavia, Italy
      Fondazione IRCCS Policlinico San Matteo
    Nov 9, 2021

    Immunological, Molecular-genetic, Image-based and Microbial

    Recruiting
    • Oncology
    • +4 more
    • Non-interventional
    • Munich, Bavaria, Germany
      LMU University Hospital
    Aug 31, 2021

    NSCLC, Stage III Trial in Germany (Durvalumab)

    Recruiting
    • NSCLC, Stage III
    • Essen, Germany
    • +3 more
    Aug 27, 2021

    NSCLC, Stage III Trial in Wuhan (Almonertinib)

    Recruiting
    • NSCLC, Stage III
    • Wuhan, Hubei, China
      Tongji Hospital of Tongji Medical College of Huazhong University
    Jul 4, 2021

    Adjuvant Therapy in Early Stage NSCLC With EGFR

    Recruiting
    • NSCLC, Stage I
    • +2 more
    • Surgeries
    • Peking, Beijing, China
    • +50 more
    Mar 31, 2021

    Lung Cancer, NSCLC Stage IV, NSCLC, Stage III Trial in Linz, Innsbruck, Salzburg

    Recruiting
    • Lung Cancer
    • +4 more
      • Linz, Oberösterreich, Austria
      • +2 more
      Dec 3, 2020

      NSCLC Stage IV, NSCLC, Stage III Trial in New Taipei City, Taipei (Oligo Fucoidan, Placebo)

      Withdrawn
      • NSCLC Stage IV
      • NSCLC, Stage III
      • Oligo Fucoidan
      • Placebo
      • New Taipei City, Taiwan
      • +2 more
      Aug 23, 2019

      The Role of Microbiota on the Development of Lung Cancer

      Unknown status
      • NSCLC, Stage I
      • +4 more
      • without intervention type
      • Wuhan, Hubei, China
        Union hospital
      May 31, 2019